AmpliPhi Biosciences to Present at Bacteriophage Therapy Workshop Sponsored by the FDA and NIH
6:50 am ET July 5, 2017 (BusinessWire) Print
AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that it has been invited to present at a workshop entitled "Bacteriophage Therapy: Scientific and Regulatory Issues" being held July 10-11, 2017 in Rockville, MD. This workshop is being organized by the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research and the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases. Further information on the workshop is available from the FDA's website, here.
This public workshop is expected to bring together an international group of government agencies, academia, industry and other stakeholders involved in research, development and regulation of bacteriophages intended for therapeutic use in humans. The aims of the workshop are to discuss the scientific and regulatory considerations for bacteriophage therapies and to provide a forum for the exchange of information and perspectives, with the ultimate goal of facilitating development and rigorous clinical assessment of bacteriophage therapy products. AmpliPhi also participated in the NIH's first workshop on bacteriophage therapy in July 2015.
AmpliPhi's Senior Scientist Susan Lehman, Ph.D., will deliver a presentation entitled "Getting from lab bench to clinic: CMC and practical considerations for phage products" on July 10, 2017, as part of an afternoon session focused on the principal regulatory issues affecting the development of bacteriophage therapy. Dr. Lehman's presentation will be available following the workshop under the company's Events & Presentation page.
